Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell LymphomaYuqin Song, Junyong Zhu, Youngil Koh et al.|Blood|2022Cited by 0